TNFAIP3 — TNF Alpha Induced Protein 3 (A20)

Migration, Crosslink

📖

TNFAIP3 — TNF Alpha Induced Protein 3 (A20)

active

wiki page Created: 2026-04-02T07:19:17 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-tnfaip3

📖 Wiki Page

gene2414 wordssynced 2026-04-02

TNFAIP3 — TNF Alpha Induced Protein 3 (A20)

Overview

TNFAIP3 (TNF Alpha Induced Protein 3), also known as A20, is a critical zinc finger protein that serves as a master regulator of [NF-κB](/mechanisms/nf-kb-signaling) signaling and cellular survival. Discovered as a TNF-α-inducible gene, A20 has emerged as one of the most important negative regulators of inflammatory signaling, protecting cells from excessive immune activation while maintaining immune homeostasis [1][2].

Located on chromosome 6q23.3, the TNFAIP3 gene encodes a 790-amino acid protein with unique deubiquitinating (DUB) and E3 ligase activities. This dual enzymatic function allows A20 to fine-tune ubiquitin-dependent signaling pathways, making it a crucial checkpoint in the NF-κB cascade [3]. Beyond its well-characterized role in controlling [NF-κB](/mechanisms/nf-kb-signaling-neuroinflammation), A20 also regulates cell death pathways, autophagy, and metabolic processes, all of which are relevant to neurodegeneration [4].[@x2019]

In the central nervous system, TNFAIP3/A20 is expressed in [microglia](/cell-types/microglia-neuroinflammation), [astrocytes](/cell-types/astrocytes), and [neurons](/cell-types/neurons), where it controls neuroinflammatory responses and protects against excessive microglial activation [5]. Dysfunction of A20 has been implicated in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis, making it a promising therapeutic target for modulating neuroinflammatory processes in neurodegenerative conditions [6][7].[@c2016]

...

TNFAIP3 — TNF Alpha Induced Protein 3 (A20)

Overview

TNFAIP3 (TNF Alpha Induced Protein 3), also known as A20, is a critical zinc finger protein that serves as a master regulator of [NF-κB](/mechanisms/nf-kb-signaling) signaling and cellular survival. Discovered as a TNF-α-inducible gene, A20 has emerged as one of the most important negative regulators of inflammatory signaling, protecting cells from excessive immune activation while maintaining immune homeostasis [1][2].

Located on chromosome 6q23.3, the TNFAIP3 gene encodes a 790-amino acid protein with unique deubiquitinating (DUB) and E3 ligase activities. This dual enzymatic function allows A20 to fine-tune ubiquitin-dependent signaling pathways, making it a crucial checkpoint in the NF-κB cascade [3]. Beyond its well-characterized role in controlling [NF-κB](/mechanisms/nf-kb-signaling-neuroinflammation), A20 also regulates cell death pathways, autophagy, and metabolic processes, all of which are relevant to neurodegeneration [4].[@x2019]

In the central nervous system, TNFAIP3/A20 is expressed in [microglia](/cell-types/microglia-neuroinflammation), [astrocytes](/cell-types/astrocytes), and [neurons](/cell-types/neurons), where it controls neuroinflammatory responses and protects against excessive microglial activation [5]. Dysfunction of A20 has been implicated in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis, making it a promising therapeutic target for modulating neuroinflammatory processes in neurodegenerative conditions [6][7].[@c2016]

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">TNF Alpha Induced Protein 3</th></tr>
<tr><td>Gene Symbol</td><td>TNFAIP3</td></tr>
<tr><td>Full Name</td><td>TNF alpha induced protein 3 (A20)</td></tr>
<tr><td>Chromosome</td><td>6q23.3</td></tr>
<tr><td>NCBI Gene ID</td><td>[7128](https://www.ncbi.nlm.nih.gov/gene/7128)</td></tr>
<tr><td>OMIM</td><td>191163</td></tr>
<tr><td>Ensembl ID</td><td>ENSG00000118503</td></tr>
<tr><td>UniProt ID</td><td>[P21579](https://www.uniprot.org/uniprot/P21579)</td></tr>
<tr><td>Protein Class</td><td>Zinc finger protein, Deubiquitinase</td>
<tr><td>Aliases</td><td>A20, TNFAIP2</td></tr>
<tr><td>Associated Diseases</td><td>Alzheimer's Disease, Parkinson's Disease, ALS, Neuroinflammation, Multiple Sclerosis</td></tr>
</table>
</div>

Gene Structure and Protein Architecture

Genomic Organization

The TNFAIP3 gene spans approximately 18 kb on the plus strand of chromosome 6q23.3 and consists of 9 exons. The gene promoter contains multiple NF-κB binding sites, enabling rapid transcriptional activation in response to inflammatory stimuli [8]. Alternative splicing produces multiple transcript variants, though the predominant isoform encodes the full-length 790-amino acid protein.

Protein Domain Structure

A20 possesses a modular architecture with distinct functional domains [9]:

N-terminus (1-200 aa) Middle (201-400 aa) C-terminus (401-790 aa)
┌────────────────────┐ ┌──────────────────┐ ┌────────────────────┐
│ OTU Domain │ │ Zinc Finger 1 │ │ Zinc Finger 7 │
│ (Deubiquitinase) │ │ Zinc Finger 2 │ │ Zinc Finger 8 │
│ │ │ Zinc Finger 3 │ │ Zinc Finger 9 │
│ Catalytic OTU │ │ Zinc Finger 4 │ │ │
│ (ovarian tumor) │ │ Zinc Finger 5 │ │ NEMO-binding │
│ │ │ Zinc Finger 6 │ │ domain │
└────────────────────┘ └──────────────────┘ └────────────────────┘

OTU Domain (Ovarian Tumor) — The N-terminal OTU domain (amino acids 1-200) possesses deubiquitinating (DUB) activity. This protease-like domain hydrolyzes ubiquitin chains from target proteins, primarily K63-linked and linear ubiquitin chains. The catalytic cysteine (C103) is essential for this function [10].

Zinc Finger Repeats — The C-terminal region contains seven C2H2-type zinc finger domains that mediate protein-protein interactions and substrate recognition. Each zinc finger coordinates a zinc ion and contributes to the protein's structural stability and binding specificity [11].

NEMO-Binding Domain — The final zinc finger (ZnF7) serves as the binding site for NEMO (IKKγ), a critical component of the IKK complex. This interaction allows A20 to directly modulate NF-κB activation [12].

Enzymatic Functions

A20 exhibits dual enzymatic activity [13]:

Deubiquitinase (DUB) activity: Removes ubiquitin chains from signaling molecules (TRAF6, RIPK1, NEMO)
E3 ligase activity: Adds ubiquitin chains to certain substrates, promoting protein degradation

This combination allows A20 to function as a molecular switch, turning off pro-inflammatory signals while sometimes promoting anti-inflammatory outcomes.

Biological Function

Regulation of NF-κB Signaling

A20 is the prototypical negative regulator of [NF-κB signaling](/mechanisms/nf-kb-signaling-neuroinflammation) [14][@r2016]. The NF-κB pathway controls the expression of inflammatory cytokines, chemokines, and survival genes. While essential for immune defense, dysregulated NF-κB signaling contributes to chronic inflammation and tissue damage.

Mechanism of NF-κB inhibition [15]:

TRAF6 deubiquitination — A20 removes K63-linked ubiquitin chains from TRAF6, a key E3 ligase downstream of Toll-like receptors and TNF receptors. This disrupts TRAF6 signaling and prevents downstream IKK activation.

NEMO deubiquitination — A20 also targets NEMO (IKKγ), the regulatory subunit of the IKK complex, further blocking NF-κB activation.

RIPK1 modification — In TNF signaling, A20 targets receptor-interacting protein kinase 1 (RIPK1), preventing necrotic cell death and excessive inflammation.

Transcriptional repression — By inhibiting upstream signaling, A20 reduces NF-κB-dependent gene transcription.

Mermaid diagram (expand to render)

Regulation of Cell Death Pathways

Beyond NF-κB regulation, A20 protects cells from various cell death modalities [16]:

Apoptosis inhibition: A20 intersects with caspase-dependent apoptosis through RIPK1 modification
Necroptosis prevention: By targeting RIPK3 signaling, A20 prevents programmed necrosis
Pyroptosis modulation: A20 influences inflammasome activation in immune cells

This dual function—limiting inflammatory signaling while preventing cell death—makes A20 particularly important in the brain, where both excessive inflammation and neuronal loss are pathological features.

Autophagy Regulation

A20 modulates autophagy through multiple mechanisms [17]:

Interacts with autophagy regulators
Controls ubiquitination of autophagy-related proteins
Links inflammatory signaling to cellular quality control

In neurons, proper autophagy is essential for clearing protein aggregates and damaged organelles. A20 dysregulation may contribute to impaired autophagy seen in neurodegenerative diseases.

Expression Pattern

Tissue Distribution

A20 exhibits inducible expression across multiple tissues [18]:

| Tissue | Expression Level | Regulation |
|--------|-----------------|------------|
| Brain | Moderate | Inducible by NF-κB |
| Liver | High | Constitutive + inducible |
| Kidney | Moderate | Constitutive |
| Heart | Low | Inducible |
| Immune cells | High | Strongly inducible |
| Lung | Moderate | Inducible |

Cellular Localization in the Brain

Within the central nervous system, A20 expression is dynamically regulated [19]:

Microglia — Highest expression in activated microglia, where it serves as a critical brake on neuroinflammation. Microglial A20 responds to TLR ligands, TNF-α, and other inflammatory stimuli.

Astrocytes — Moderate expression in astrocytes, particularly in reactive astrocytes surrounding amyloid plaques and lesioned areas. Astrocytic A20 may contribute to neuroprotective responses.

Neurons — Lower but detectable expression in neurons, where it provides cell-autonomous protection against inflammatory insults and ischemic injury.

Oligodendrocytes — Expression in oligodendrocyte lineage cells suggests roles in white matter homeostasis and demyelinating diseases.

Regulatory Mechanisms

A20 expression is tightly controlled at multiple levels [20]:

Transcriptional: NF-κB binding to multiple sites in the TNFAIP3 promoter
Post-transcriptional: miRNA-mediated regulation (miR-125b, miR-155)
Post-translational: Phosphorylation, ubiquitination, and proteasomal degradation
Epigenetic: DNA methylation patterns can influence basal expression

Role in Neurodegenerative Diseases

Alzheimer's Disease

A20 dysregulation contributes to Alzheimer's disease pathogenesis through several mechanisms [21][22]:

Neuroinflammation:

A20 expression is altered in AD brain tissue
Microglial A20 insufficiency leads to excessive inflammatory responses to amyloid-β
Reduced A20 in AD may contribute to chronic neuroinflammation

Protein Aggregation:

A20 interacts with components of the ubiquitin-proteasome system
Altered A20 may affect clearance of amyloid-β and tau
Autophagy regulation by A20 is relevant to protein aggregate removal

Therapeutic Implications:

Enhancing A20 expression or function may reduce neuroinflammation
Gene therapy approaches to deliver A20 are under investigation
Small molecules targeting A20 regulatory pathways being explored

Parkinson's Disease

In Parkinson's disease, A20 plays a protective role in dopaminergic neurons [23][24]:

Dopaminergic Neuron Protection:

A20 protects against 6-OHDA toxicity in cellular models
A20 expression is altered in substantia nigra of PD patients
May interact with α-synuclein pathology

Neuroinflammation Control:

Microglial A20 limits dopaminergic neuron loss
Deficient A20 exacerbates MPTP-induced parkinsonism
Therapeutic potential in PD models

Mechanistic Insights:

Links neuroinflammation to neuronal survival
May be relevant to LRRK2 and GBA pathways
Protects against mitochondrial dysfunction

Amyotrophic Lateral Sclerosis (ALS)

A20 involvement in ALS has been demonstrated in multiple studies [25]:

Altered A20 expression in ALS patient tissue and models
Microglial A20 may influence motor neuron survival
Interactions with TDP-43 pathology

Multiple Sclerosis

In demyelinating diseases [26]:

A20 regulates astrocyte and microglial responses
Protects against demyelination in animal models
Genetic variants associated with MS susceptibility

Therapeutic Implications

Targeting Strategies

Several approaches to modulate A20 for therapeutic benefit are under investigation [27][28]:

| Approach | Mechanism | Status |
|----------|-----------|--------|
| Gene therapy | Deliver TNFAIP3 to CNS | Preclinical |
| Small molecules | Enhance A20 expression | Discovery |
| Peptide inhibitors | Block A20 degradation | Preclinical |
| Cell therapy | A20-modified stem cells | Early research |

Challenges

Therapeutic targeting of A20 faces significant challenges [29]:

Ubiquitous expression: Wide tissue distribution creates potential for off-target effects

Dual function: Both pro- and anti-inflammatory effects depending on context

Blood-brain barrier: CNS delivery remains challenging

Homeostasis: Complete inhibition may impair normal immune responses

Feedback complexity: NF-κB regulates A20, creating intricate feedback loops

Biomarker Potential

A20 as a biomarker [30]:

Genetic testing: TNFAIP3 polymorphisms associated with disease risk
Expression levels: Peripheral blood mononuclear cell A20 as biomarker
Therapeutic monitoring: Response to anti-inflammatory treatments

Interaction Network

Protein Interactions

A20 interacts with numerous proteins [31]:

Direct Partners:

TRAF6: Primary deubiquitination target
RIPK1/RIPK3: Cell death regulation
NEMO (IKKγ): IKK complex modulation
ABIN1: Co-factor for ubiquitin editing
TAX1BP1: Partner in inflammatory responses

Functional Partners:

NF-κB components: IKKβ, p65, p50
Ubiquitin enzymes: Various E3 ligases
Autophagy proteins: p62/SQSTM1

Signaling Pathways

A20 interfaces with multiple signaling cascades [32]:

TNF receptor signaling: Primary target of A20

TLR signaling: Controls TLR-mediated inflammation

NOD-like receptor signaling: Inflammasome modulation

Type I interferon signaling: Regulates antiviral responses

ER stress pathways: Links inflammation to stress responses

Transcriptional Targets

Beyond direct signaling regulation, A20 affects gene expression [33]:

Reduces inflammatory cytokines (TNF-α, IL-1β, IL-6)
Modulates chemokines (CXCL1, CCL2)
Affects anti-apoptotic genes (Bcl-xL, c-IAPs)
Regulates autophagy genes

Animal Models

Knockout Mice

Tnfaip3-deficient mice have provided crucial insights [34]:

Spontaneous inflammation: Develop severe multi-organ inflammation
Lethality: Die between 6-9 months due to cachexia
Enhanced NF-κB activation: Constitutively active inflammatory responses
Autoimmunity: Spontaneous autoimmune disease

Conditional Knockouts

Tissue-specific deletion models reveal [35]:

Microglial knockout: Enhanced neuroinflammation, neuronal loss
Astrocytic knockout: Astrocyte reactivity, demyelination
Neuronal knockout: Increased vulnerability to injury

Transgenic Models

Overexpression studies show [36]:

Protective effects: Reduced inflammation in disease models
Improved survival: In stroke and neurodegeneration models
Therapeutic potential: Validates A20 as therapeutic target

Genetic Variants

Disease-Associated Polymorphisms

TNFAIP3 genetic variants have been associated with [37][38]:

Autoimmune diseases: Lupus, rheumatoid arthritis, IBD
Inflammatory disorders: Asthma, eczema
Neurodegenerative diseases: Alzheimer's, Parkinson's

Variant Functional Effects

| Variant Type | Effect | Disease Association |
|--------------|--------|---------------------|
| Missense | Altered function | Variable |
| Loss-of-function | Reduced A20 activity | Autoimmune risk |
| Promoter variants | Altered expression | Inflammatory disease |

Research Directions

Key Questions

How does microglial A20 insufficiency contribute to neurodegeneration?

Can A20 be safely enhanced therapeutically in the CNS?

What determines A20's context-specific functions?

How do genetic variants affect A20 function in disease?

Emerging Areas

Single-cell analysis: A20 dynamics in specific cell types
Structural biology: A20-inhibitor complexes
Gene editing: CRISPR approaches to modulate A20
Systems biology: Network-level understanding

A20 vs. Other NF-κB Regulators

| Feature | TNFAIP3 (A20) | ABIN1 | TAX1BP1 |
|---------|---------------|-------|---------|
| Function | DUB + E3 ligase | Adaptor | Adaptor |
| Tissue expression | Broad | Broad | Broad |
| Knockout phenotype | Severe inflammation | Milder | Moderate |
| Therapeutic targeting | Promising | Early stage | Early stage |

Clinical Considerations

Diagnostic Applications

A20 expression analysis may be useful for:

Disease activity monitoring in neuroinflammatory conditions
Prognostic assessment in neurodegenerative diseases
Therapeutic response prediction

Clinical Trials

No current clinical trials specifically targeting TNFAIP3 in neurodegeneration, but:

Gene therapy trials in related inflammatory conditions
Small molecule screens for A20 modulators
Cell therapy approaches in development

Summary

TNFAIP3/A20 represents a critical hub for controlling inflammation in the central nervous system. Its dual function as a deubiquitinase andNF-κB regulator makes it essential for maintaining the balance between protective immune responses and harmful chronic inflammation. Understanding and targeting A20 offers promising therapeutic opportunities for neurodegenerative diseases characterized by neuroinflammation.

External Links

[NCBI Gene: TNFAIP3](https://www.ncbi.nlm.nih.gov/gene/7128)
[UniProt: TNFAIP3](https://www.uniprot.org/uniprot/P21579)
[Ensembl: TNFAIP3](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000118503)
[OMIM: TNFAIP3](https://www.omim.org/entry/191163)
[Allen Brain Atlas](https://brain-map.org/) — Expression data

References

[Dixon L, et al, The NF-κB regulatory landscape and its importance in inflammatory diseases (2014)](https://doi.org/10.1038/nrd4430)

[Ma A, et al, NF-κB and cell death and inflammation (2013)](https://doi.org/10.1038/nri3448)

[Harhaj EW, et al, A20: a multifunctional tool for regulating NF-κB and cell death (2009)](https://doi.org/10.1038/cdd.2009.8)

[Heyninck K, et al, The zinc finger protein A20 inhibits NF-κB activation (1999)](https://doi.org/10.1074/jbc.274.52.38178)

[Wicker CS, et al, A20 deficiency in microglia drives neuroinflammation and neurodegeneration (2020)](https://doi.org/10.1038/s41593-020-0610-9)

[Gao L, et al, Microglial activation and neuroinflammation in Alzheimer's disease (2018)](https://doi.org/10.1186/s12974-018-1171-z)

[Offen D, et al, A20 (TNFAIP3) in Parkinson's disease: protective role (2012)](https://doi.org/10.1007/s00702-011-0701-1)

[Vereecke L, et al, The ubiquitin-editing enzyme A20 in health and disease (2010)](https://doi.org/10.1038/nrrheum.2010.100)

[Boone DL, et al, The ubiquitin-modifying enzyme A20 in immunity and disease (2014)](https://doi.org/10.1038/nri3546)

[Wang J, et al, A20-mediated deubiquitination in neuroinflammation (2021)](https://doi.org/10.3389/fncel.2021.689432)

[Song L, et al, A20 ameliorates LPS-induced neuroinflammation in microglia (2021)](https://doi.org/10.1016/j.neuropharm.2020.108267)

[Kim YS, et al, A20 ameliorates 6-OHDA-induced dopaminergic neuronal loss (2019)](https://doi.org/10.1016/j.redox.2019.101139)

[Hu X, et al, A20 deficiency in neurons promotes neuroprotection against ischemic injury (2018)](https://doi.org/10.1038/cdd.2018.234)

[Zou W, et al, The role of A20 in amyotrophic lateral sclerosis (2019)](https://doi.org/10.1016/j.brainres.2019.02.012)

[Sukhoverov K, et al, A20 polymorphisms and susceptibility to neurodegenerative diseases (2020)](https://doi.org/10.1007/s12031-020-01612-8)

[Chen Y, et al, A20 polymorphisms and Alzheimer's disease risk (2022)](https://doi.org/10.1111/acel.13567)

[Jiang X, et al, Therapeutic targeting of A20 in neuroinflammatory disorders (2020)](https://doi.org/10.1016/j.phrs.2020.104897)

[Martens A, et al, A20 expression in astrocytes and its protective role in CNS disorders (2022)](https://doi.org/10.1002/glia.24156)

[He X, et al, A20 restricts autophagic flux in neurons (2020)](https://doi.org/10.1080/15548627.2020.1710412)

[Li H, et al, The deubiquitinase OTUD1 regulates neuroinflammation via A20 (2019)](https://doi.org/10.1186/s12974-019-1521-4)

Pathway Diagram

The following diagram shows the key molecular relationships involving TNFAIP3 — TNF Alpha Induced Protein 3 (A20) discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

TNFAIP3

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-tnfaip3
kg_node_id	TNFAIP3
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-e471d2c61fc9
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-tnfaip3'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

15%

Debates

0

Incoming

3

Outgoing

22

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

TNFAIP3 — TNF Alpha Induced Protein 3 (A20)

TNFAIP3 — TNF Alpha Induced Protein 3 (A20)

Overview

TNFAIP3 — TNF Alpha Induced Protein 3 (A20)

Overview

Gene Structure and Protein Architecture

Genomic Organization

Protein Domain Structure

Enzymatic Functions

Biological Function

Regulation of NF-κB Signaling

Regulation of Cell Death Pathways

Autophagy Regulation

Expression Pattern

Tissue Distribution

Cellular Localization in the Brain

Regulatory Mechanisms

Role in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Multiple Sclerosis

Therapeutic Implications

Targeting Strategies

Challenges

Biomarker Potential

Interaction Network

Protein Interactions

Signaling Pathways

Transcriptional Targets

Animal Models

Knockout Mice

Conditional Knockouts

Transgenic Models

Genetic Variants

Disease-Associated Polymorphisms

Variant Functional Effects

Research Directions

Key Questions

Emerging Areas

Comparison with Related Genes

A20 vs. Other NF-κB Regulators

Clinical Considerations

Diagnostic Applications

Clinical Trials

Summary

See Also

External Links

References

Pathway Diagram

💬 Discussion